Skip to main content

Together we are beating cancer

Donate now

Leukaemia

Showing 12 out of 129 results
Cancer Research UK logo

Cancer Research Technology (CRT) - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia. Cancer Research Technology (CRT) - Cancer Research UK's development and commercialisation arm has teamed up with The University of Auckland to advance the discovery of new molecular targeted compounds for the treatment of leukaemia.

by Cancer Research Technology (CRT) | News | 22 April 2010

22 April 2010

Cancer Research UK logo

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charityїs development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody * drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday). CANCER RESEARCH UK and Cancer Research Technology (CRT), the charityїs development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody * drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

by Cancer Research UK | News | 4 January 2010

4 January 2010

Cancer Research UK logo

CANCER RESEARCH UK SCIENTISTS have discovered a completely new route by which leukaemia develops, according to research published in Nature. CANCER RESEARCH UK SCIENTISTS have discovered a completely new route by which leukaemia develops, according to research published in Nature.

by Cancer Research UK | News | 28 September 2009

28 September 2009

Cancer Research UK logo

The opening of a unique centre today (Wednesday) will put Newcastle at the forefront of cancer research and bring benefits to patients in the North East. The opening of a unique centre today (Wednesday) will put Newcastle at the forefront of cancer research and bring benefits to patients in the North East.

by Cancer Research UK | News | 1 July 2009

1 July 2009

Cancer Research UK logo

Scientists have pinpointed an enzyme responsible for breaking down and inactivating a key childhood leukaemia drug, which could help to explain why around 20 per cent of patients do not respond to therapy. Their findings are published in the Journal of Clinical Investigation* today (Monday). Scientists have pinpointed an enzyme responsible for breaking down and inactivating a key childhood leukaemia drug, which could help to explain why around 20 per cent of patients do not respond to therapy. Their findings are published in the Journal of Clinical Investigation* today (Monday).

by Cancer Research UK | News | 8 June 2009

8 June 2009